In this weeks video, Dr. Brian G.M. Durie explains the results of the A.R.R.O.W. trial, which proved the efficacy and safety of once-a-week dosing of Kyprolis for myeloma patients.
BOTTOM LINE:
The FDA approval of once-weekly dosing of Kyprolis is effective, more convenient for patients, and doesnt lead to additional toxicities.